^
Association details:
| Biomarker: | KIT expression |
|---|---|
| Cancer: | Leukemia |
| Drug: | opelkibart elmanitin (MGTA-117) (c-KIT-targeted antibody-drug conjugate, RNA polymerase 2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemic Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML)
Published date:
11/04/2020
Excerpt:
To demonstrate anti-leukemic activity of MGTA-117, we studied it in multiple human leukemic xenograft murine models that mimic untreated and refractory AML, including both cell line derived (Kasumi-1, CD117-expressing leukemia cell line, in NSG mice) and patient derived (AML PDX 1: J000106134, treatment naïve AML PDX and AML PDX 2: J000106132, heavily pretreated relapsed refractory AML PDX in NSG-SGM3 mice) xenograft models….Furthermore, a single dose of MGTA-117 significantly decreased peripheral tumor burden leading to delayed tumor growth resulting in a 2-3.3 fold and 1.3-1.8 fold increase in median survival in the treatment naïve AML PDX 1 and highly pretreated AML PDX 2 models (respectively) compared to vehicle…
DOI:
https://doi.org/10.1182/blood-2020-140422
